isradipine has been researched along with Metabolic Syndrome in 1 studies
Isradipine: A potent antagonist of CALCIUM CHANNELS that is highly selective for VASCULAR SMOOTH MUSCLE. It is effective in the treatment of chronic stable angina pectoris, hypertension, and congestive cardiac failure.
Metabolic Syndrome: A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components of metabolic syndrome include ABDOMINAL OBESITY; atherogenic DYSLIPIDEMIA; HYPERTENSION; HYPERGLYCEMIA; INSULIN RESISTANCE; a proinflammatory state; and a prothrombotic (THROMBOSIS) state.
| Excerpt | Relevance | Reference |
|---|---|---|
| "5-5 mg/twice daily of isradipine, a dihydropyridine calcium channel blocker, in hypertensive patients with features of the metabolic syndrome." | 7.73 | Efficacy and tolerability of rilmenidine compared with isradipine in hypertensive patients with features of metabolic syndrome. ( Sirotiaková, J; Widimský, J, 2006) |
| "5-5 mg/twice daily of isradipine, a dihydropyridine calcium channel blocker, in hypertensive patients with features of the metabolic syndrome." | 3.73 | Efficacy and tolerability of rilmenidine compared with isradipine in hypertensive patients with features of metabolic syndrome. ( Sirotiaková, J; Widimský, J, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Widimský, J | 1 |
| Sirotiaková, J | 1 |
1 other study available for isradipine and Metabolic Syndrome
| Article | Year |
|---|---|
Efficacy and tolerability of rilmenidine compared with isradipine in hypertensive patients with features of metabolic syndrome.
Topics: Adult; Aged; Antihypertensive Agents; Blood Glucose; Blood Pressure; Double-Blind Method; Drug Toler | 2006 |